Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.85−0.29 (-9.08%)
Close on Nov 18, 2026Market cap $49.05MP/E –Yield –
Verrica Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Verrica Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$28.38M. For fiscal 2025 it was -$12.19M. The highest annual figure on record is -$4.46M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.19M | – |
| FY2024 | Dec 31, 2024 | -$65.92M | – |
| FY2023 | Dec 31, 2023 | -$65.76M | – |
| FY2022 | Dec 31, 2022 | -$21.30M | – |
| FY2021 | Dec 31, 2021 | -$30.91M | – |
| FY2020 | Dec 31, 2020 | -$40.18M | – |
| FY2019 | Dec 31, 2019 | -$30.08M | – |
| FY2018 | Dec 31, 2018 | -$21.88M | – |
| FY2017 | Dec 31, 2017 | -$4.46M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$13.10M | -967.4% |
| Q1 FY2026 | Mar 31, 2026 | -$9.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.19M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.63M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.21M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.92M | -1751.7% |
| Q2 FY2023 | Jun 30, 2023 | -$11.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.21M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.45M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.41M | -12450.0% |
| Q4 FY2021 | Dec 31, 2021 | -$8.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.73M | – |
| Q1 FY2021 | Mar 31, 2021 | $60.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.63M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.52M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.03M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.33M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.89M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.43M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.36M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.10M | – |
| Q1 FY2017 | Mar 31, 2017 | -$570.00K | – |
See a number that looks wrong?